Quality of Life in Patients With Primary Sclerosing Cholangitis
| Status: | Recruiting |
|---|---|
| Conditions: | Gastrointestinal, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/1/2019 |
| Start Date: | July 1, 2016 |
| End Date: | December 30, 2019 |
| Contact: | Andrew Muir, MD |
| Email: | andrew.muir@duke.edu |
| Phone: | 919-684-2052 |
Quality of Life in Primary Sclerosing Cholangitis
The purpose of this study is to assess the healthcare-related quality of life (HRQOL), the
impact of risk of liver transplant and risk of malignancy on HRQOL, and the complementary and
alternative medicine use in patients with PSC.
impact of risk of liver transplant and risk of malignancy on HRQOL, and the complementary and
alternative medicine use in patients with PSC.
A cohort of adult (age ≥ 18) patients with a diagnosis of PSC will be identified. The
patients will be approached about participating in the study while at their appointment,
either by the investigators or someone else known to the patient. If the patient agrees, the
investigators or other key personnel will then provide information about the study and obtain
their informed consent to participate.
The patients who consent to participate will be sent home from the clinic with a survey to
complete and return via mail in a provided addressed, stamped envelope. The survey consists
of the Short Form-36 (SF-36), the Chronic Liver Disease Questionnaire (CLDQ), questions from
the PROMIS SexFs v2.0, questions regarding perceived risk for liver transplant,
cholangiocarcinoma, and colorectal carcinoma, as well as perceived overall life expectancy,
and questions regarding complementary and alternative medicine use.
Demographic information and clinical data will also be obtained from the patient's electronic
medical record. The study will be cross-sectional in nature, and there will be no follow-up
with the subjects after the survey is completed.
patients will be approached about participating in the study while at their appointment,
either by the investigators or someone else known to the patient. If the patient agrees, the
investigators or other key personnel will then provide information about the study and obtain
their informed consent to participate.
The patients who consent to participate will be sent home from the clinic with a survey to
complete and return via mail in a provided addressed, stamped envelope. The survey consists
of the Short Form-36 (SF-36), the Chronic Liver Disease Questionnaire (CLDQ), questions from
the PROMIS SexFs v2.0, questions regarding perceived risk for liver transplant,
cholangiocarcinoma, and colorectal carcinoma, as well as perceived overall life expectancy,
and questions regarding complementary and alternative medicine use.
Demographic information and clinical data will also be obtained from the patient's electronic
medical record. The study will be cross-sectional in nature, and there will be no follow-up
with the subjects after the survey is completed.
Inclusion Criteria:
- Adult (age ≥ 18) patients with PSC, confirmed by laboratory tests, imaging, and/or
liver biopsy
Exclusion Criteria:
- Patients <18
- Patients who have undergone liver transplant, patients with frank hepatic
encephalopathy
- Patients with active inflammatory bowel disease (IBD) flares
- Patients with malignancies
- Patients unable to understand English
- Patients refusing to participate or provide informed consent
We found this trial at
1
site
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
Click here to add this to my saved trials
